Navigation Links
Rockland Immunochemicals Awarded Phase I SBIR Funding to Develop Novel Agents for Cancer Diagnosis and Targeted Therapy

Gilbertsville, PA (PRWEB) October 28, 2013

Rockland Immunochemicals Inc. today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute, National Institutes of Health (NCI/NIH) to develop nanoprobes for in vivo imaging of cancer cells and tumors that express one of the three important cancer therapeutic targets: EGFR, Her2 and Mesothelin. This project is a joint collaboration between Rockland and Abzyme Therapeutics with in vivo imaging consultants from Yale University and the University of Pittsburgh.

Medical imaging is a key component in the clinical management of cancer patients. Cancer imaging agents are used in conjunction with medical imaging equipment and, by highlighting the contrast between normal and malignant tissues, allow the collection of information on cancer presence and progression. Developing novel imaging agents that can be used for imaging and targeted radiotherapy of cancer would greatly enhance the efficacy of the cancer patient management and help usher in a new era of personalized cancer therapy.

According to market research firm Markets and Markets, the global diagnostic imaging market, which stood at $20.7 billion in 2010, is expected to swell to $26.6 billion by 2016. This expected rise is attributed to an aging population, increasing awareness about preventive care, and advancements in the field.

In Phase 1, Rockland and Abzyme Therapeutics will develop, label, and characterize high-affinity single domain antibodies (sdAbs) against EGFR, Her2 and Mesothelin. Under the terms of this grant, Abzyme Therapeutics will develop single domain antibodies and Rockland will be responsible for bioconjugation and in vivo characterization.

“Despite significant scientific progress, very few cancer imaging agents are available in the clinic,” commented Carl A Ascoli, PhD, Laboratory Director at Rockland Immunochemicals. “The size, ease of manufacture, and condition-resistant nature of sdAbs make them the best choice as capture molecules. We expect that our sdAb imaging agents will have superiority over other agents designed for in vivo and in situ biodetection and diagnosis.”

“In these times of shrinking government investment in research, this SBIR grant validates Rockland’s business model of collaboration with leading academic institutions to aggregate, develop and commercialize technologies that will ultimately benefit humanity,” continued Jim Fendrick, President and CEO of Rockland Immunochemicals. “This research is in line with the company’s expertise in antibodies and antibody based tools. We are confident that this collaboration will generate significant innovation and that the results will have great scientific and commercial applications.”

In the planned Phase II portion of this project, the key antibodies will be radionuclide labeled and characterized using PET scanners in collaboration with Yale University and University of Pittsburg. Radionuclide labeled antibodies specific to cancer cells can be used not only as in vivo imaging agents but also for targeted cancer therapy.

About Rockland Immunochemicals
Rockland Immunochemicals has supported the academic, biopharma and diagnostic industries with antibodies and antibody based tools™ for basic research, assay development and preclinical studies for over 50 years. With facilities in Pennsylvania, Rockland manufactures over 10,000 products ideally suited for integration into critical assays such as western blotting, immunohistochemistry (IHC), immunofluorescence microscopy (IF), ELISA and FLOW cytometry. Additional information about Rockland Immunochemicals’ Life Science Tools and services can be found on the company’s website at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. $9 million grant awarded to UH to study, treat learning disabilities
3. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
4. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
5. Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students
6. Southeast program to fight diabetes awarded nearly $10 million by HHS
7. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
8. 29 Johns Hopkins stem cell researchers awarded funding
9. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
10. FirstVitals Health and Wellness, Inc. awarded $4 Million CMS Innovation Grant for Unique Telehealth Diabetes Progam Focused on Glycemic Control and Prevention of Diabetic Foot Complications
11. EMBO Gold Medal 2012 awarded to Jiri Friml
Post Your Comments:
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... carried out by the University of Toronto and the University of British Columbia suggested ... hospitalizations for head injuries. The article explains that part of the reason for the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... safe and convenient way to dispense prescription medications at home, so he invented ... way to monitor and dispense prescription medications. In doing so, it could help ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a ... X. With ProSidebar: Fasion, video editors can easily add an informative sidebar to ... title opener. Utilize presets featuring self-animating drop zones, lines, bars, and text with ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A simply groundbreaking ... is an interesting show that delves into an array of issues that are presently ... could benefit from open dialogue, this show is changing the subjects consumers focus on, ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women on ... organizations in the country. They have overseen financial turnarounds, shown commitment to their ... healthcare industry as a whole through their advocacy and professional efforts. , Becker's ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 --> ... to use SyMRI to find optimal contrast weighting of MRI ... metastases, and has signed a research agreement with SyntheticMR in ... hospital. Using SyMRI, it is possible to generate multiple contrast ... after the patient has left, thus making it possible to ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
Breaking Medicine Technology: